

# Product data sheet



|   |   |  |
|---|---|--|
| MedKoo Cat#: 407213<br>Name: A-1155463<br>CAS#: 1235034-55-5<br>Chemical Formula: C <sub>35</sub> H <sub>32</sub> FN <sub>5</sub> O <sub>4</sub> S <sub>2</sub><br>Exact Mass: 669.1880<br>Molecular Weight: 669.79 |   |  |
| Product supplied as:  | Powder  |  |
| Purity (by HPLC):   | ≥ 98%   |  |
| Shipping conditions   | Ambient temperature   |  |
| Storage conditions:   | Powder: -20°C 3 years; 4°C 2 years.<br>In solvent: -80°C 3 months; -20°C 2 weeks. |  |

## 1. Product description:

A-1155463 is a highly potent and selective BCL-XL inhibitor. A-1155463 is substantially more potent against BCL-XL-dependent cell lines relative to WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.

## 2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

## 3. Solubility data

| Solvent | Max Conc. mg/mL | Max Conc. mM |
|---------|-----------------|--------------|
| DMSO    | 50              | 74.65        |

## 4. Stock solution preparation table:

| Concentration / Solvent Volume / Mass | 1 mg    | 5 mg    | 10 mg    |
|---------------------------------------|---------|---------|----------|
| 1 mM                                  | 1.49 mL | 7.47 mL | 14.93 mL |
| 5 mM                                  | 0.30 mL | 1.49 mL | 2.99 mL  |
| 10 mM                                 | 0.15 mL | 0.75 mL | 1.49 mL  |
| 50 mM                                 | 0.03 mL | 0.15 mL | 0.30 mL  |

## 5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

## 6. Recommended literature which reported protocols for in vitro and in vivo study

### In vitro study

- Zhang H, Xue J, Hessler P, Tahir SK, Chen J, Jin S, Souers AJ, Levenson JD, Lam LT. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. *Mol Cancer*. 2015 Jul 2;14:126. doi: 10.1186/s12943-015-0397-y. PMID: 26134786; PMCID: PMC4487849.
- Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Levenson JD. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). *Blood Cancer J*. 2015 Nov 13;5(11):e368. doi: 10.1038/bcj.2015.88. Erratum in: *Blood Cancer J*. 2016;6:e403. PMID: 26565405; PMCID: PMC4670945.

### In vivo study

- Sun WC, Pei L. Dexmedetomidine attenuates propofol-induced apoptosis of neonatal hippocampal astrocytes by inhibiting the Bcl2l1 signalling pathway. *Eur J Neurosci*. 2021 Dec;54(11):7775-7789. doi: 10.1111/ejn.15517. Epub 2021 Nov 23. PMID: 34734676.
- Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y,

# Product data sheet



Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Levenson JD, Elmore SW, Souers AJ. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. doi: 10.1021/ml5001867. PMID: 25313317; PMCID: PMC4190639.

## 7. Bioactivity

### Biological target:

---

A-1155463 is an inhibitor of Bcl-xL ( $K_i = <0.01$  nM).<sup>1</sup> It is selective for Bcl-xL over Bcl-2 and Bcl-W ( $K_i$ s = 80 and 16 nM, respectively). A-1155463 inhibits the growth of H146 small cell lung cancer cells ( $EC_{50} = 65$  nM). In vivo, A-1155463 (5 mg/kg, i.p.) reduces tumor volume in an H146 mouse xenograft model. A-1155463 also induces premature apoptosis in influenza A-infected cells ( $EC_{50} = <10$  nM). A-1155463 has an  $EC_{50}$  of 70 nM in Molt-4 cell.

### In vitro activity

---

This article demonstrates the utility of A-1155463 in investigating the role of BCL-X(L) in mediating the survival of specific tumor types. Colorectal cancer cell lines with BCL2L1 copy number  $>3$  were more sensitive to A-1155463. Cell lines with high expression of BCL-XL and NOXA were sensitive to A-1155463.

Reference: Mol Cancer. 2015 Jul 2;14:126. <https://pubmed.ncbi.nlm.nih.gov/26134786/>

### In vivo activity

---

A-1155463 is an excellent tool molecule for studying BCL-XL biology and is a productive lead structure for further optimization. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses.

Reference: ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. <https://pubmed.ncbi.nlm.nih.gov/25313317/>

*Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.*